Aims: We have previously shown that the combination of pravastatin and sarpogrelate is synergistically beneficial for atherosclerosis. In this study, we investigated whether the pravastatin-sarpogrelate combination was sufficient for treatment in an old mouse model of atherosclerosis or if additional intervention would be needed to address the newly included aging factor and its complex pathophysiological impact on the atherosclerogenic state. We added an anti-TNF biological to the combination treatment cocktail because of the known pathologic roles of TNF in the aging process.
| INTRODUCTION
Statin is a cholesterol-decreasing agent that inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase and is used in the treatment of cardiovascular diseases (CVD). 1 Although statins are widely used to prevent CVD, interest is raising as the risk of diabetes increases. Pravastatin is recommended over other statins for the treatment of patients with atherosclerosis and those at high risk for diabetes.
2
Sarpogrelate is an antiplatelet agent widely used to prevent serotonin receptor antagonists and arterial thrombosis. 3 However, as only two studies have been published in rabbits, little is known about its effect on atherosclerosis. 4, 5 Sarpogrelate slows the progression of rabbit atherosclerosis by increasing endothelial nitric oxide synthase (eNOS) 4 and increasing blood viscosity. 5 Because platelets and coagulation systems are critical to the progression of atherosclerosis, the combination of pravastatin and sarpogrelate helps prevent atherosclerosis more effectively. 6 Atherosclerosis is a crucial disease in CVD patients. The arterial wall thickens because of the accumulation of fat-rich macrophages (foam cells) and the proliferation of fibrous and smooth muscle cells, which is caused by complicated inflammatory processes that produce atherosclerotic plaques. 7 Elevated levels of inflammatory cytokines in the aging process play important roles in promoting vascular damage and exacerbating atherosclerosis. 8 Etanercept is a biodrug that treats inflammatory autoimmune diseases by interfering with tumor necrosis factor (TNF). Anti-TNF therapy clearly reduces the frequency of heart failure and CVD in patients with rheumatoid arthritis. 9 In addition, TNF antagonists have been reported to have beneficial effects in preventing progression of patients with atherosclerosis. 10 Therefore, we hypothesized that adding an agent that blocked TNF to the pravastatin-sarpogrelate combination would be more effective for the treatment of age-incorporated atherosclerosis.
In this study, we investigated the therapeutic efficacy of a novel triple combination, pravastatin, sarpogrelate, and etanercept in an aging model of atherosclerosis. 
| MATERIALS AND METHODS

| Experimental animals
| Histochemistry and immunohistochemistry
A tissues preparation was performed as previously described. 6 Briefly, blood was collected from the mice after 12 weeks of breeding. The aorta and heart were perfused with PBS under anesthesia and col- Harris hematoxylin (YD Diagnostics, Seoul, Korea), and morphometric data were obtained using a slide scanner (APERIO CS2; Leica).
| Serum lipid analysis and cytokine determination
Blood was retro-orbitally collected in each group of mice, stored at −80°C, and used for histological analysis (n=6-7/group). Serum total cholesterol, triglyceride, high-density lipoprotein cholesterol (HDL), and low-density lipoprotein cholesterol (LDL) were measured by
Hitachi 7020 (Hitachi, Tokyo, Japan). Tumor necrosis factor (TNF) (Max; BioLegend Inc, San Diego, CA, USA), and interleukin (IL)-6 (Max;
BioLegend Inc) levels were measured using an enzyme-linked immunoassay kit according to the manufacturer's instructions using serum.
| Statistical analysis
Data are expressed as mean SEM, and statistical analysis was performed using the Student's t test (GraphPad Prism software, GraphPad, San Diego, CA, USA). P≤.05 was considered significantly different.
| RESULTS
| Both the pravastatin and sarpogrelate double combination and etanercept-added triple combination show an antagonistic effect on the progress of atherosclerosis in old LDLr KO mice
Although the combination of pravastatin and sarpogrelate is effective in attenuating atherosclerosis in young mice, 6 its activity is incomplete in the context of the complex underlying pathogenesis of aging and atherosclerosis. We investigated whether adding etanercept to pravastatin and sarpogrelate therapy could improve the protective effect of pravastatin and sarpogrelate therapy. Histochemical localization of total cholesterol in the aortic lesions of atherosclerosis is known to be consistent through ORO staining 11 and is easily identified as red areas. ORO staining showed a significant reduction in HFD-induced plaque areas on the en face aortic preparations in the pravastatin (40 mg/kg BW) plus sarpogrelate (50 mg/ kg BW) and the pravastatin-sarpogrelate-etanercept (20 mg/kg BW)
triple-combination groups ( Figure 1A,B) . Although statistically insignificant, the etanercept-added triple group showed a strong trend toward plaque reduction comparing to the double-combination group.
However, the etanercept-only treatment generated similar atherosclerotic plaque areas to the control group. 
| Total cholesterol and LDL cholesterol decreased only in the pravastatin-sarpogrelate-etanercept triple therapy group
Weight gain after 12 weeks of HFD and drug treatment in aged mice was not different between groups (Table 1A) . After 12 weeks of drug treatment, serum lipid levels were analyzed. Only the pravastatinsarpogrelate-etanercept triple therapy was effective in lowering total cholesterol and LDL levels compared to the HFD-control group (Table 1B) . The pravastatin plus sarpogrelate therapy and etanercept alone groups showed insignificant changes in lipid levels compared
The triple-combination therapy of pravastatin, sarpogrelate, and etanercept attenuates atherosclerotic lesion area of the aorta artery in LDLr KO mice. Male elderly LDLr KO mice were fed a NFD or a HFD for 12 wk and were treated with etanercept (5 mg/kg IP three times weekly), the pravastatin and sarpogrelate combination (40 and 50 mg/kg, respectively, orally five times weekly), the pravastatin, sarpogrelate, and etanercept combination (40 and 50 mg/kg, respectively, orally five times weekly; 5 mg/kg IP three times weekly), or vehicle for 12 wk. F I G U R E 3 Significant suppression of TNF production by the pravastatin/sarpogrelate/etanercept triple-combination therapy. Inflammatory cytokines were analyzed with enzyme-linked immunosorbent assay kits. Briefly, blood was retro-orbitally collected before surgery to harvest the aorta. Serum was isolated, and tumor necrosis factor (TNF) (A) and interleukin (IL)-6 (B) were measured. Error bars represent the standard errors, and significance was analyzed by Student's t test (*P<.05, **P<.01, compare to HFD, N=6-7/group). NFD, normal-fat diet; HFD, high-fat diet; PRA, pravastatin; SAR, sarpogrelate; ETA, etanercept; MPK, mg/kg body weight to the control group. The mean change in total cholesterol levels was −30% in the triple-combination group. The mean change in LDL levels in the triple therapy group was −33%.
| DISCUSSION
Despite the efficacy of statin for atherosclerosis, statin monotherapy is not sufficient to reach the therapeutic goals of many patients. 12 Multiple studies have compared statin monotherapy with a combination of statins and other lipid-modifying drugs, but data on the combination of statins and nonlipid-modifying drugs are limited. Previously, we reported that the addition of an antiplatelet agent, sarpogrelate, to pravastatin synergistically ameliorated atherosclerosis compared to pravastatin alone in a young (8-week-old) mouse model.
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Because the major atherosclerosis population in clinical practice is elderly patients, we raised LDLr KO mice until they were 60 weeks old and tested the efficacy of the pravastatin-sarpogrelate combination therapy in the aged mouse model. Although the double-combination therapy significantly reduced plaque areas on the en face aortic preparations as expected (Figure 1 ), the therapy did not affect the plaque areas of aortic roots or the expression of ICAM-1, MOMA-2, and TNF (Figures 2 and 3 ), contrary to our previous results using the young (8-week-old) AS mouse model. 6 Moreover, the lipid-lowering effect of pravastatin was not evident in aged mice (Table 1) . Here, we provide evidence for the first time that statin does not efficiently lower cholesterol levels in aged AS mice.
A previous study showed that high levels of TNF were associated with a high prevalence of atherosclerosis in the elderly cohort. 13 Based on this study, we added etanercept to the pravastatin-sarpogrelate combination regimen to incorporate a TNF-neutralizing mechanism into a new aging-related atherosclerosis treatment strategy. In this study, we evaluated the effect of a triple-combination regimen of pravastatin, sarpogrelate, and etanercept in elderly LDLr KO mice for the first time.
Although etanercept exerted antiaging vasculoprotective effects 14 and TNF antagonists showed a advantageous effect on preventing the progression of subclinical atherosclerosis, etanercept, and TNF antagonists remain controversial regarding the favorable effects on the CV system. 10 In our study, etanercept alone (5 mg/kg BW) did not play an antagonistic role in the development of atherosclerosis in the elderly LDLr KO mice.
Therefore, we tried a novel triple therapy with pravastatin, sarpogrelate, and etanercept to control atherosclerosis in aged LDLr KO mice. As a result, we found that only the triple combination reduced the development of aging-related atherosclerosis, as evidenced by reduced plaque area, improved histology, low level of TNF in serum, and lowered lipid levels. Decreased TNF levels in serum by etanercept ( Figure 3A) could possibly reduce ICAM-1 expression ( Figure 2B ) as well as monocyte/macrophage infiltration ( Figure 2C ). And these anti-TNF-related activities combined with reduction of lipid levels by pravastatin and an antiplatelet effect of sarpogrelate could synergistically contribute the overall alleviation of aging-associated atherosclerosis.
We demonstrated for the first time that the addition of etanercept to the statin-antiplatelet regimen in the presence of aging factors could maximize the antiatherosclerotic effects. The excellent effect of triple-combination therapy indicates that this therapy may serve as a novel strategy for managing aging-related CVD with its underlying complex immunological and pathological factors.
